4D Molecular Therapeutics FDMT Return on invested capital

Return on invested capital at other companies

Eli LillyLLY

39.7%+10.3pp

Regeneron PharmaceuticalsREGN

10.3%-1.5pp

Vertex PharmaceuticalsVRTX

28.4%+1.4pp

EyePoint, Inc.EYPT

-228.9%-1,528pp

AbbVieABBV

17.1%—

RegenxbioRGNX

-103.9%+612pp

FAQ

What is 4D Molecular Therapeutics's return on invested capital?

4D Molecular Therapeutics (FDMT) reported return on invested capital of -51.1% in Q1 2026.

How has 4D Molecular Therapeutics's return on invested capital changed year-over-year?

4D Molecular Therapeutics's return on invested capital increased by 12.1% year-over-year, from -58.2% to -51.1%.

What is the long-term trend for 4D Molecular Therapeutics's return on invested capital?

Over 3 years (2022 to 2025), 4D Molecular Therapeutics's return on invested capital has grown at a -11.1% compound annual growth rate (CAGR), from -58.3% to -40.9%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.